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Objective: This post hoc analysis of 10 US study sites from a long-term open-label phase 3 study of adjunctive
cenobamate evaluated the efficacy of cenobamate in patients with prior epilepsy-related surgery.
Methods: Patients with uncontrolled focal seizures despite taking stable doses of 1–3 concomitant antiseizure
medications (ASMs) received increasing doses of cenobamate (12.5, 25, 50, 100, 150, 200 mg/day) at 2-week
intervals over 12 weeks (target dose, 200 mg/day). Further increases up to 400 mg/day using biweekly 50mg/day increments were allowed during the maintenance phase. Dose adjustments of cenobamate and
concomitant ASMs were allowed. Data were assessed until the last clinic visit on or after September 1, 2019.
Results: Of the 240 eligible patients, 85 had prior epilepsy-related surgery and 155 were nonsurgical patients.
Baseline focal seizure frequency per 28 days was numerically higher among prior surgery (mean=25.9/
median=4.1/range=0.3–562.3) versus nonsurgical (mean=13.8/median=2.4/range=0.2–534.2) patients.
Among all patients, 100 % seizure reduction ≥ 12 months at any consecutive month interval occurred in 30.6 %
(26/85) prior surgery and 39.4 % (61/155; p > 0.05) nonsurgical patients (cenobamate treatment median
duration=32.9 months). Among the 177 patients still receiving cenobamate at the data cutoff, 29.2 % (19/65) of
prior surgery and 36.6 % (41/112; p > 0.05) of nonsurgical patients had 100 % seizure reduction ≥ 12 months at
the data cutoff. Cenobamate was well tolerated.
Conclusions: This post hoc analysis supports the efficacy of cenobamate in patients with refractory focal seizures
despite prior surgery. These findings suggest cenobamate may be considered early in the treatment regimen,
including, in some patients, before surgery is considered.
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1. Introduction
More than one-third of patients with newly diagnosed epilepsy have
continued seizures despite treatment with two or more antiseizure
medications (ASMs), and the likelihood of additional patients achieving

seizure freedom (100 % seizure reduction) diminishes with each added
ASM (Chen et al., 2018). Epilepsy surgery can be an effective treatment
option for selected patients following failure of adequate treatment trials
with at least two ASMs; however, approximately half of these patients
may continue to experience focal seizures at 5 years post-surgery (de Tisi

Abbreviations: ASMs, antiseizure medications; AVM, arteriovenous malformation; C021, ClinicalTrials.gov NCT02535091; DNET, dysembryoplastic neuro
epithelial tumor; MedDRA, Medical Dictionary for Regulatory Activities; RNS, responsive neurostimulation; TEAEs, treatment-emergent adverse events; VNS, vagus
nerve stimulation.
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et al., 2011; Mohan et al., 2018). Treatment options following failed
surgery include consideration of additional surgery or adjust
ments/additions to the patient’s ASM regimen. The percentage of pa
tients achieving complete seizure freedom at 2 years post-surgery
declines with each successive surgery (58 % at first surgery, 49 % at
second surgery, 39 % at third or more surgeries) suggesting “surgical
refractoriness” (Yardi et al., 2020). Studies examining further trials of
ASM treatment following failed epilepsy surgery are limited but suggest
fewer than 10 % of these patients may achieve long-term seizure
freedom (Ma et al., 2020; Ryzí et al., 2015).
Cenobamate (SK Life Science, Inc.) is an ASM approved in the US
(XCOPRI®) and Europe (ONTOZRY®) for the treatment of adults with
focal seizures. Two randomized, double-blind, placebo-controlled phase
2 studies in patients with uncontrolled focal seizures who were taking
stable doses of 1–3 ASMs showed significantly reduced focal seizure
frequency with adjunctive cenobamate treatment (Chung et al., 2020;
Krauss et al., 2020). In these studies, 28 % of patients receiving cen
obamate 200 mg/day (vs 9 % placebo) and 21 % of patients receiving
cenobamate 400 mg/day (vs 1% placebo) achieved 100 % seizure
reduction (ie, zero seizures) during their 6-week and 12-week mainte
nance phases, respectively (Chung et al., 2020; Krauss et al., 2020). A
large (N = 1347), global, phase 3, open-label safety study
(NCT02535091; C021) showed that lowering the starting dose of cen
obamate to 12.5 mg and titrating every other week resulted in good
safety and tolerability, as shown in high long-term retention of patients
(Sperling et al., 2020). Reporting of seizures was not required in the
C021 safety study because long-term efficacy was not assessed; however,
a protocol amendment permitted post hoc collection of seizure data from
seizure diaries and clinic seizure records from 10 US C021 study sites
that had high-quality, long-term seizure data recorded (Sperling et al.,
2021). A post hoc analysis of this subset of patients from C021 found
sustained seizure reduction and high rates of seizure freedom (~36 % of
patients) for ≥ 12 months (Sperling et al., 2021).
The current post hoc analysis of the 10 US study sites within the
global phase 3 C021 study examined the efficacy of cenobamate treat
ment in patients with uncontrolled focal seizures who had prior
epilepsy-related surgery (ie, prior surgery). The surgeries included
resection, corpus callosotomy, tumor removal, ablation, vagus nerve
stimulation (VNS), and responsive neurostimulation (RNS). The efficacy
of cenobamate in patients with prior surgery and uncontrolled focal
seizures has not previously been reported. This post hoc analysis was
performed to evaluate cenobamate treatment in this patient group with
particularly treatment-resistant seizures.

weeks and then every 1–3 months (Sperling et al., 2021).
For the post hoc analysis, eligible sites were those in the US that
enrolled ≥ 11 patients who had recorded high-quality seizure data
(Sperling et al., 2021). To be included, patients had to have (1) ≥ 1 focal
aware motor, focal impaired awareness, or focal to bilateral tonic-clonic
seizure per 13 weeks baseline prior to the screening visit, (2) focal aware
motor, focal impaired awareness, or focal to bilateral tonic-clonic
seizure data for evaluation (if any seizures occurred) while on treat
ment, (3) raw seizure data consistently documented, and (4) seizure data
of good quality for ≥ 85 % of time spent in the study. Focal seizure data
were available for 240 patients from 10 eligible US study sites. The
median duration of cenobamate exposure for all patients in the post hoc
analysis was 30.2 months (range 0.10–43 months) and 177 patients
were still receiving cenobamate as of the data cutoff on or after
September 1, 2019 (Sperling et al., 2021).
The C021 primary study was conducted in accordance with the In
ternational Conference on Harmonisation Good Clinical Practice
guidelines (Sperling et al., 2020). An independent ethics committee or
institutional review board approved the study protocol, amendments,
and post hoc analysis. Each patient provided written informed consent
prior to participation in C021 and no new consent was required for the
post hoc analysis.
2.2. Assessments and data analysis
The post-hoc analysis evaluated patients with prior epilepsy-related
surgery or no surgery. Prior surgeries included resection, corpus cal
losotomy, lesionectomy/tumor removal, laser ablation therapy, VNS,
and RNS. Patients with or without prior epilepsy-related surgery were
examined for 100 % seizure reduction efficacy outcomes. Three efficacy
outcomes were assessed: (1) the percentage of all patients achieving 100
% seizure reduction ≥ 12 months at the last clinic visit (ie, interval in
cludes the last clinic visit for the patient prior to discontinuation or data
cutoff); (2) the percentage of all patients achieving 100 % seizure
reduction at any consecutive ≥ 12-month interval during exposure to
cenobamate (ie, does not have to include the last visit); and (3) the
percentage of patients who were still receiving cenobamate who ach
ieved 100 % seizure reduction ≥ 12 months at the data cutoff visit (ie,
interval includes the data cutoff visit). Patients with any missing seizure
frequency data could not be counted as having 100 % seizure reduction.
Safety was assessed by treatment-emergent adverse events (TEAEs)
coded using the Medical Dictionary for Regulatory Activities (MedDRA)
version 20.0. Demographic and clinical characteristics of patients with
prior surgery versus nonsurgical patients were analyzed using twosample t-tests (α = 0.05, 2-sided) for comparisons of mean group dif
ferences and using Fisher’s exact test for comparisons of group differ
ences in percentages of patients. Patients with prior surgery and
nonsurgical patients were compared on the efficacy outcomes using
Fisher’s exact test. All other numerical differences in efficacy and safety
data were summarized descriptively.

2. Methods
2.1. Study design and participants
Details of the study design and patient eligibility for the C021 global,
multicenter, open-label safety study have been reported (Sperling et al.,
2020). Following a screening period of up to 21 days and a 12-week
titration phase, the open-label maintenance phase continued for a
total study duration of up to 43 months in the post hoc analysis efficacy
subset of patients (Sperling et al., 2021). Eligible patients were 18–70
years old with a diagnosis of focal epilepsy (as defined by the Interna
tional League Against Epilepsy seizure classification criteria (Fisher
et al., 2017; Scheffer et al., 2017) and uncontrolled focal seizures despite
treatment with 1–3 concomitant ASMs at stable doses (Sperling et al.,
2020). Cenobamate treatment began at 12.5 mg/day for 2 weeks, fol
lowed by 25 mg/day for 2 weeks and 50 mg/day for 2 weeks. The dose
was then increased by 50 mg/day at 2-week intervals to a target dose of
200 mg/day, and further increases up to 400 mg/day using biweekly
increments of 50 mg/day were allowed during the maintenance phase.
Cenobamate dose reduction was allowed (minimum dose was 50
mg/day) based on investigators’ clinical judgment. Cenobamate mon
otherapy was not allowed. Patient visits occurred every 2 weeks for 16

3. Results
3.1. Patients
Of the 240 patients who were eligible to participate in the post hoc
efficacy analysis of the C021 study, 85 (35.4 %) had prior surgery and
155 (64.6 %) had no prior surgery. The patients with prior surgery on
average were younger than the nonsurgical patients (p = 0.012), had a
slightly higher percentage of male patients (p > 0.05), and a higher
percentage of White patients (p = 0.023) (Table 1). Patients with prior
surgery had a numerically higher focal seizure frequency at baseline,
with a mean (25.9 seizures/28 days) and median (4.1 seizures/28 days)
monthly seizure frequency that was approximately double that of the
nonsurgical patients (mean 13.8 and median 2.4 seizures/28 days) (p >
0.05). A numerically higher percentage of the patients with prior
2
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Table 1
Demographic and clinical characteristics for cenobamate patients with and
without prior epilepsy-related surgery.

Mean (min, max) age (years) at
screening
Male/Female, n (%)
Race (n, %)
White
Black or African American
Hispanic
Asian
Seizure typea, n (%)
Focal aware motor
Focal impaired awareness
Focal to bilateral tonic-clonic
All patients mean/median (min,
max) baseline seizure
frequency/28 days
Patients with < 3 baseline
seizures/28 days mean/ median
baseline seizure frequency/28
days
Patients with < 3 baseline
seizures/28 days, n (%)
Patients with ≥ 3 baseline
seizures/28 days mean/ median
baseline seizure frequency/28
days
Patients with ≥ 3 baseline
seizures/28 days, n (%)
No. of concomitant ASMs at
baseline (n, %)
1
2
3
Concomitant ASMs at baseline >
15% (n, %)
Lacosamide
Levetiracetam
Lamotrigine
Zonisamide
Clobazam

Prior surgery
patients (n =
85)

Nonsurgical
patients (n =
155)

Pvalue

38.6 (18, 69)

43.6 (18, 70)

0.012

54 (63.5)/31
(36.5)

81 (52.3)/74
(47.7)

0.104

80 (94.1)
3 (3.5)
2 (2.4)
0

123 (79.4)
18 (11.6)
10 (6.5)
4 (2.6)

14 (16.5)
78 (91.8)
24 (28.2)
25.9/4.1 (0.3,
562.3)

13 (8.4)
146 (94.2)
32 (20.6)
13.8/2.4 (0.2,
534.2)

0.086
0.589
0.203
0.201

1.6/1.5

1.5/1.4

0.452

35 (41.2)

92 (59.4)

43.0/9.9

31.8/7.9

0.010
b
0.515

50 (58.8)

63 (40.6)

3 (3.5)
46 (54.1)
36 (42.4)

26 (16.8)
85 (54.8)
44 (28.4)

37 (43.5)
26 (30.6)
23 (27.1)
15 (17.6)
21 (24.7)

61 (39.4)
63 (40.6)
43 (27.7)
24 (15.5)
17 (11.0)

Table 2
Type and location of prior epilepsy-related surgeries.

0.023

Surgery, n (%)

Prior surgery patients (n =
85)

VNS/RNS
Temporal lobectomya
Right temporal
Left temporal
Extratemporal resection
Right
Left
Tumor-related resectionb
Right frontal meningioma
Inferior right frontal and temporal
oligodendroglioma
Calcified right parietal ganglioglioma
Left frontal neuroblastoma
Left frontal glioma
Left temporal ganglioma
Left temporal DNET
Hypothalamic hamartoma
Corpus callosotomy
Ablation
Right parietal AVM
Left frontal

45 (52.9)
29 (34.1)
18 (21.2)
11 (12.9)
13 (15.3)
5 (5.9)
8 (9.4)
8 (9.4)
1 (1.2)
1 (1.2)
1 (1.2)
1 (1.2)
1 (1.2)
1 (1.2)
1 (1.2)
1 (1.2)
6 (7.1)
2 (2.4)
1 (1.2)
1 (1.2)

Some patients had multiple procedures.
AVM, arteriovenous malformation; DNET, dysembryoplastic neuroepithelial
tumor; RNS, responsive neurostimulation; VNS, vagus nerve stimulation.
a
Some of the temporal lobectomy patients also had extratemporal resections
that are not included in the table resection count.
b
The tumor-related resections are not included in the temporal or extra
temporal resection counts.

0.010
b
0.002

3.2. Patient retention
The percentage of patients who continued cenobamate treatment at
data cutoff (retention rate) was 76.5 % (65/85) for patients with prior
surgery and 72.3 % (112/155) for nonsurgical patients, with treatment
up to 43 months (median duration of cenobamate treatment was 32.9
months). When patients who continued cenobamate were examined by
type of surgery, retention rate was 72.5 % (29/40) for patients with prior
resection, ablation, or disconnection surgery, 74.2 % (23/31) for pa
tients with VNS or RNS, and 92.9 % (13/14) for patients with both
resection or disconnection surgery and VNS.

0.583
0.128
1.000
0.716
0.009

Comparisons of mean group differences were based on two-sample t-tests (α =
0.05, 2-sided). Comparisons of group differences in percentages of patients were
based on Fisher’s exact test.
a
Patients may be reported in more than one category.
b
The four-group comparison of baseline seizure frequency (ie, percentage of
patients with prior surgery versus nonsurgical patients with <3 versus ≥3
baseline seizures/28 days) was based on Fisher’s exact test.

3.3. Cenobamate dose
The mean dose of cenobamate was higher among patients with prior
surgery who continued cenobamate treatment (n = 65; 313.8 mg/day)
versus the nonsurgical patients who continued cenobamate treatment
(n = 112; 270.5 mg/day) at data cutoff. Within subgroups of surgical
procedures, the mean dose of cenobamate in patients continuing treat
ment was 329.3 mg/day in patients with prior resection, ablation, or
disconnection surgery (n = 29), 302.2 mg/day in patients with prior
VNS or RNS surgery (n = 23), and 300.0 mg/day in patients with both
resection or disconnection surgery and VNS (n = 13).

surgery versus the nonsurgical patients also had focal aware motor (16.5
% vs 8.4 % of patients) and focal to bilateral tonic-clonic seizures (28.2
% vs 20.6 % of patients) (p-values > 0.05). A significantly greater per
centage of patients with prior surgery had ≥ 3 baseline seizures per 28
days and a significantly greater percentage of nonsurgical patients had
< 3 baseline seizures per 28 days (p = 0.010). A significantly greater
percentage of patients with prior surgery were receiving 3 ASMs at
baseline (42.4 % vs 28.4 % of patients, p = 0.002). Most notable among
the concomitant ASMs at baseline was the higher percentage of patients
with prior surgery receiving clobazam compared with the nonsurgical
patients (p = 0.009).
Approximately half of the patients with prior surgery had VNS or
RNS, 34.1 % had a temporal lobectomy, 15.3 % had an extratemporal
resection, 9.4 % had a tumor-related resection, 7.1 % had a corpus
callosotomy, and 2.4 % had an ablation (Table 2). Across these surgeries,
40 patients (47.1 %) had ≥ 1 procedure that was not VNS or RNS, 31
patients (36.5 %) had VNS (n = 30) or RNS (n = 2, including 1 patient
with both VNS and RNS) only, and 14 patients (16.5 %) had both VNS
and a resection or disconnection surgery.

3.4. Efficacy
In the patients with prior surgery, 23.5 % (20/85) had 100 % seizure
reduction ≥ 12 months at the last clinic visit and 30.6 % (26/85) had
100 % seizure reduction at any consecutive ≥ 12-month interval (Fig. 1),
compared with 27.1 % (42/155) and 39.4 % (61/155), respectively, of
the nonsurgical patients (p-values > 0.05). Among the 177 patients still
receiving cenobamate at the data cutoff, 29.2 % (19/65) of patients with
prior surgery versus 36.6 % (41/112) of the nonsurgical patients had
100 % seizure reduction for ≥ 12 months at the data cutoff (p > 0.05). In
a subgroup analysis, 100 % seizure reduction ≥ 12 months at data cutoff
was examined by baseline seizure frequency in patients with prior
3
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Fig. 1. . 100 % seizure reduction with cenobamate treat
ment in patients with prior epilepsy-related surgery and
with no surgery. P-values are based on Fisher’s exact test of
patients with prior epilepsy-related surgery versus
nonsurgical patients. At last clinic visit: interval includes
the last clinic visit for the patient prior to discontinuation
or data cutoff (includes all patients with prior surgery). At
any consecutive 12-month interval: does not have to
include the last visit (includes all patients with prior sur
gery). At data cutoff visit: interval includes the data cutoff
visit (includes patients continuing on cenobamate at data
cutoff).

surgery and nonsurgical patients. Among the patients with < 3 baseline
seizures per 28 days, 41.7 % (10/24) of patients with prior surgery and
45.5 % (30/66) of nonsurgical patients had 100 % seizure reduction ≥
12 months at data cutoff. Among the patients with ≥ 3 baseline seizures
per 28 days, 21.9 % (9/41) of patients with prior surgery and 23.9 %
(11/46) of nonsurgical patients had 100 % seizure reduction ≥ 12
months at data cutoff.
Seizure reduction was examined by surgery groups. In the first
comparison, the group of patients with prior resection, ablation, or
disconnection surgery was compared to the group of patients with prior
VNS or RNS, and the 14 “overlapping” patients who had both resection
or disconnection surgery and VNS were included in each of these two
groups (Fig. 2A). The percentage of patients with prior resection, abla
tion, or disconnection surgery (with or without VNS) who had 100 %
seizure reduction for ≥ 12 months with cenobamate treatment for any
consecutive interval (35.2 %) was higher than the percentage of patients
with prior VNS or RNS (with or without resection or disconnection
surgery; 26.7 %) and slightly lower than the percentage of nonsurgical
patients (39.4 %) (Fig. 2A). In the patients who continued cenobamate,
the percentage of patients with 100% seizure reduction for ≥ 12 months
at data cutoff was similar in the patients with prior resection, ablation,
or disconnection surgery (with or without VNS; 28.6 %) compared with
patients with prior VNS or RNS (with or without resection or discon
nection surgery; 30.6 %) and was slightly lower than in the nonsurgical
patients (36.6 %) (Fig. 2A). In the second comparison among surgery
groups, the 100 % seizure reduction for ≥ 12 months at data cutoff
among patients who continued cenobamate was similar for the group of
patients with prior resection, ablation, or disconnection surgery only
(27.6 % of patients), the group of patients with prior VNS or RNS only
(30.4 %), and the group of patients with prior resection or disconnection
surgery along with VNS (30.8 %) (Fig. 2B). The percentage of patients
with 100 % seizure reduction for ≥ 12 months at any consecutive ≥ 12
months interval and at data cutoff when examined by the specific type of
surgery are shown in Table 3.

occurred in more than 1 patient with prior surgery included 6 patients
with seizure (7.1 %) and 2 patients each (2.4 %) with ataxia, mental
status changes, urinary tract infection, and vomiting. The serious TEAEs
that occurred in more than 1 nonsurgical patient included 2 patients
each (1.3 %) with chest pain, pneumonia, post-traumatic epilepsy,
postictal paralysis, postictal state, and pulmonary embolism. Discon
tinuation of cenobamate due to TEAEs occurred in 8.2 % of prior surgery
patients and 15.5 % of nonsurgical patients (Table 4). TEAEs that led to
discontinuation in more than 1 patient included somnolence (n = 2; 2.4
%) in prior surgery patients and ataxia, dizziness, and somnolence (each
n = 2; 1.3 %) in nonsurgical patients.
4. Discussion
Patients with focal seizures that remain uncontrolled despite
adequate trials with two or more ASMs and epilepsy surgery have
particularly treatment-resistant seizures. Few studies have specifically
examined whether adjusting/adding ASMs in patients for whom prior
epilepsy-related surgery has failed can result in 100 % seizure reduction
for these patients. In a retrospective review of medical records that
examined the response to ASMs after surgery failure (ie, recurrence of
seizures) in 103 consecutive patients with a minimum 2-year follow-up,
patients tried an average of 4.02 ASMs; 9.7 % of patients attained seizure
freedom and 72.8 % of patients had no change in focal seizures with
ASM adjustments (Ma et al., 2020). Similarly, in a retrospective study of
34 patients who had no change in their seizures at 1 year following
epilepsy surgery, long-term follow-up for an average of 7.6 years found
that only 3 patients (8.8 %) achieved seizure freedom following a change
in ASMs alone (4 others became seizure-free following resective reop
eration and one after VNS) (Ryzí et al., 2015). The duration of 100%
seizure reduction was not stated in these studies.
The current post hoc analysis of adjunctive cenobamate treatment in
patients with prior surgery and uncontrolled focal seizures examined
long-term (≥12 months) 100 % seizure reduction in patients treated in a
subset of clinical sites from the C021 open-label study (Sperling et al.,
2021; Sperling et al., 2020). Among all patients with prior surgery, 30.6
% had long-term 100 % seizure reduction at any interval of ≥ 12
consecutive months. In the patients with prior surgery who continued
taking cenobamate until data cutoff, 29.2 % had long-term 100 %
seizure reduction for ≥ 12 months before the data cutoff visit. These
outcomes were slightly lower than those of the nonsurgical patients
(39.4 % any interval and 36.6 % at data cutoff had long-term 100 %

3.5. Safety
Fatigue, dizziness, and somnolence were the most common TEAEs in
patients with prior surgery (40.0 %, 38.8 %, and 25.9 %, respectively)
and in nonsurgical patients (31.6 %, 28.4 %, and 31.6 %, respectively)
(Table 4). Serious TEAEs were reported by 29.4 % of patients with prior
surgery versus 16.1 % of nonsurgical patients. The serious TEAEs that
4
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Fig. 2. 100 % seizure reduction with cenobamate treatment in patients with prior epilepsy-related surgery by (A) resection, ablation, disconnection (with or without
VNS), or VNS/RNS (with or without resection or disconnection) surgery and (B) by resection, ablation, disconnection surgery versus VNS/RNS surgery versus
resection/disconnection and VNS. RNS, responsive neurostimulation; VNS, vagus nerve stimulation.

seizure reduction for ≥12 months). However, the patients with prior
surgery had a higher seizure burden, with on average double the fre
quency of seizures versus the nonsurgical patients at baseline.
These percentages of patients with prior surgery achieving long-term
100 % seizure reduction in response to cenobamate treatment are sub
stantially greater than seen in previous reports of patients with failed
epilepsy surgery who experienced seizure freedom (Ma et al., 2020; Ryzí
et al., 2015). The percentage of patients with prior surgery who had 100
% seizure reduction ≥ 12 months with cenobamate treatment was also
considerably higher than that reported with other ASMs, with < 13 % of
patients achieving ≥ 12 months of seizure freedom, in open-label
extension studies of phase 2 and phase 3 trials of lacosamide, per
ampanel, and brivaracetam in patients with focal seizures (Husain et al.,
2012; Krauss et al., 2018; Toledo et al., 2016).
When evaluated by type of surgery, a higher percentage of patients in
the current study with prior resection, ablation, or disconnection sur
gery (with or without VNS) had long-term 100 % seizure reduction at
any interval compared with patients who had prior VNS or RNS (with or
without resection or disconnection surgery; slightly more than a third of
patients versus slightly more than a quarter of patients, respectively).
Among the patients who continued cenobamate treatment at data cutoff,
the percentage of patients with long-term 100 % seizure reduction at

data cutoff was similar between patients with both prior resection or
disconnection surgery and prior VNS and patients with VNS or RNS only,
and the percentage of patients with prior resection, ablation, or
disconnection surgery only was slightly lower. Altogether, these out
comes support the efficacy of cenobamate in achieving long-term 100 %
seizure reduction in patients with highly refractory seizures.
Patients with prior surgery who continued cenobamate treatment
were receiving a higher dosage of cenobamate than the nonsurgical
patients at data cutoff. The highest average dose of cenobamate at data
cutoff occurred in the group of patients who had prior resection, abla
tion, or disconnection surgery. Cenobamate treatment was well toler
ated in patients with prior surgery, and the most common TEAEs were
central nervous system-related, similar to the nonsurgical patients.
Although the percentage of patients with TEAEs was slightly higher in
the prior surgery patients than in the nonsurgical patients, discontinu
ation due to TEAEs was lower in the prior surgery patients. Clinicians
were allowed to make adjustments to concomitant ASMs during the
C021 study (Rosenfeld et al., 2021; Sperling et al., 2020), and dose re
ductions of concomitant ASMs may have mitigated TEAEs in prior sur
gery patients who on average received higher doses of cenobamate
compared with nonsurgical patients. The most common serious TEAE in
patients with prior surgery was seizure, reported by 6 patients, which is
5
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that was associated with initiation of levetiracetam (de Tisi et al., 2011).
A possible limitation of post-surgery treatment with levetiracetam is the
greater incidence of psychiatric and behavioral adverse events in the
patient group with failed epilepsy surgery as compared with nonsurgical
patients (Habets et al., 2017; Motamedi et al., 2003).
Limitations of this study analysis include that the C021 study was an
open-label safety study that was not designed to assess efficacy, and thus
efficacy was analyzed post hoc. The C021 study was also not designed to
evaluate efficacy in patients with prior epilepsy-related surgery. As a
result, some details of patients’ prior surgeries were not available,
including pre-surgery magnetic resonance imaging and electroenceph
alogram findings and the extent of each patient’s seizure reduction
response to surgery prior to seeking additional ASM treatment. The
study lumped together patients who had resective surgery, which is
potentially curative, with patients who had palliative procedures,
making the surgery group heterogeneous. Finally, because this post hoc
analysis retrospectively evaluated patients from a subset of 10 clinical
sites from the C021 study, there is the possibility of selection bias,
although it should be noted that the subset cohort generally resembled
the remaining C021 study sample (Sperling et al., 2021). Despite these
limitations, a key strength of the C021 outcomes is their clinical practice
relevance because the study was long-term and clinicians were allowed
to make adjustments to the cenobamate dose as well as to concomitant
ASMs (Rosenfeld et al., 2021; Sperling et al., 2020).
The decision to continue ASM trials or pursue epilepsy surgery in
patients with treatment-refractory focal seizures requires evaluation of
the benefits and risks of either choice (Kwan and Sperling, 2009). While
surgery in appropriately selected cases may have significant benefits in
seizure reduction, it has potential medical, neurologic, and psychiatric
complications, some of which could be irreversible (Kwan and Sperling,
2009). The post hoc efficacy analysis of the C021 study has demon
strated sustained improvement in seizure control in adults with uncon
trolled focal seizures who were treated with cenobamate (Sperling et al.,
2021). High rates of sustained 100 % seizure reduction across focal
seizure types and high retention of patients across the analysis period
support long-term efficacy and tolerability of cenobamate (Sperling
et al., 2021). This was demonstrated within the context of dose reduc
tion and discontinuation of one or more concomitant ASMs to improve
tolerability during the addition of cenobamate to an existing ASM
regimen (Rosenfeld et al., 2021). Along with the current post hoc
analysis showing long-term 100 % seizure reduction for any interval of
≥ 12 consecutive months in 30.6 % of patients with prior surgery, these
outcomes support treatment with cenobamate early in the ASM treat
ment regimen. A trial of cenobamate may be considered before surgery
(with the exception of tumor-related resections). The merits of this
approach may be evaluated in a future trial of cenobamate in patients
being considered for epilepsy surgery. It is probably appropriate to
consider cenobamate prior to repeated epilepsy surgery, where the odds
of achieving seizure freedom are reduced (Malmgren and Edelvik, 2017;
Yardi et al., 2020).

Table 3
100 % seizure reduction ≥ 12 months by type of surgery.
100 % seizure reduction ≥ 12 months (n/N, %)

Temporal lobectomya
Right side lobectomy
Left side lobectomy
Extratemporal resection
Right side resection
Left side resection
Tumor-related resection
b
Corpus callosotomy
Ablation
VNS/RNS
VNS (no RNS)
RNS (no VNS)
RNS and VNS

Any consecutive ≥ 12
months

≥ 12 months at data
cutoff

12/29 (41.4)
9/18 (50.0)
3/11 (27.3)
4/13 (30.8)
0/5 (0)
4/8 (50.0)
2/8 (25.0)

8/29 (27.6)
6/18 (33.3)
2/11 (18.2)
3/13 (23.1)
0/5 (0)
3/8 (37.5)
0/8 (0)

2/6 (33.3)
0/2 (0)
12/45 (26.7)
11/43 (25.6)
0/1 (0)
1/1 (100.0)

2/6 (33.3)
0/2 (0)
11/45 (24.4)
10/43 (23.3)
0/1 (0)
1/1 (100.0)

Some patients had multiple procedures.
RNS, responsive neurostimulation; VNS, vagus nerve stimulation.
a
Some of the temporal lobectomy patients also had extratemporal resections
that are not included in the table resection count.
b
The tumor-related resections are not included in the temporal or extra
temporal resection counts.
Table 4
Most common TEAEs in patients with prior epilepsy-related surgery and with no
surgery.
TEAEs, n (%)

Prior surgery
patients (n = 85)

Nonsurgical patients
(n = 155)

Patients with ≥ 1 TEAE
Patients with ≥ 1 TEAE leading to
discontinuation
Patients with ≥ 1 serious TEAE
TEAEs in ≥ 10 % of patients
Fatigue
Dizziness
Somnolence
Balance disorder
Upper respiratory tract
infection
Headache
Seizure
Depression
Weight decreased
Constipation
Vomiting
Fall
Nausea

85 (100)
7 (8.2)

151 (97.4)
24 (15.5)

25 (29.4)

25 (16.1)

34
33
22
17
13

49
44
49
20
25

(40.0)
(38.8)
(25.9)
(20.0)
(15.3)

11 (12.9)
10 (11.8)
10 (11.8)
10 (11.8)
9 (10.6)
9 (10.6)
8 (9.4)
7 (8.2)

(31.6)
(28.4)
(31.6)
(12.9)
(16.1)

25 (16.1)
7 (4.5)
9 (5.8)
14 (9.0)
12 (7.7)
13 (8.4)
17 (11.0)
21 (13.5)

TEAEs, treatment-emergent adverse events.

not unexpected given the treatment-refractory seizures in this patient
group. Treatment retention rates are an indicator of overall treatment
satisfaction, including efficacy, safety, and tolerability, as each patient
decides whether to continue treatment (Ben-Menachem et al., 2010;
Chung et al., 2007). The high retention rate of 76.5 % for patients with
prior surgery indicates cenobamate was an effective and tolerable
treatment over a treatment period of up to 43 months.
One other ASM has been specifically evaluated in patients following
failed epilepsy surgery. A retrospective study of levetiracetam, primarily
as adjunctive treatment, in patients with recurrent focal seizures
following epilepsy surgery examined seizure freedom in the last 3
months of treatment and found high short-term seizure freedom in pa
tients with prior epilepsy surgery (10/21 patients; 47.6 %), considerably
greater than in a comparison group of nonsurgical patients (9/61, 14.7
%) (Motamedi et al., 2003). Alternatively, a long-term follow-up study
of epilepsy surgery reported 15.1 % of patients experienced seizure
freedom (duration not reported) starting at 2 or more years after surgery

5. Conclusions
In this post hoc analysis, high rates of sustained 100 % seizure
reduction ≥ 12 months were achieved with cenobamate in adult pa
tients with uncontrolled focal seizures who were refractory to prior
epilepsy-related surgery as well as to 1–3 ASMs. These findings support
the efficacy of cenobamate even in patients with very refractory seizures
despite surgery. They suggest that cenobamate should be considered
early in the treatment regimen, including, in some patients, prior to
considering surgical treatment.
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